Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Non Operating Income (2017 - 2023)

Denali Therapeutics (DNLI) has disclosed Non Operating Income for 7 consecutive years, with $13.1 million as the latest value for Q4 2023.

  • On a quarterly basis, Non Operating Income rose 97.13% to $13.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was $51.5 million, a 248.62% increase, with the full-year FY2023 number at $51.5 million, up 248.62% from a year prior.
  • Non Operating Income was $13.1 million for Q4 2023 at Denali Therapeutics, down from $14.4 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $14.4 million in Q3 2023 to a low of $1.0 million in Q3 2021.
  • A 5-year average of $4.8 million and a median of $3.3 million in 2019 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: crashed 61.58% in 2021, then skyrocketed 763.38% in 2023.
  • Denali Therapeutics' Non Operating Income stood at $3.8 million in 2019, then crashed by 57.2% to $1.6 million in 2020, then dropped by 21.17% to $1.3 million in 2021, then skyrocketed by 418.29% to $6.7 million in 2022, then skyrocketed by 97.13% to $13.1 million in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Non Operating Income are $13.1 million (Q4 2023), $14.4 million (Q3 2023), and $12.9 million (Q2 2023).